First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J. Davis, Janice M. Mehnert, Sarah P. Blagden et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 93
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective AnalysisLawrence Liu, Angela C. Hirbe, Carina Dehner et al.|Genes|2022Cited by 13